中药制剂治疗2型糖尿病的系统评价再评价

Chinese Patent Preparations for Treatment of Type 2 Diabetes Mellitus:An Overview of Systematic Review

目的对中药制剂治疗2型糖尿病的Meta分析/系统评价进行再评价。方法计算机检索PubMed、Web of Science、Wiley、中国知网、维普、万方等6个数据库,检索时限均为建库至2021年12月31日。应用AMSTAR-2量表、PRISMA声明对纳入的31篇文献进行质量和规范性评价。结果AMSTAR-2方法学质量评价结果显示,所纳入的Meta分析/系统评价中有21篇评分为极低等级,3篇为低等级,7篇为中等等级,无高等级文献,主要降级因素为随访期限和利益冲突未说明;PRISMA评分为14-26分,平均得分约为21.6分,其中大部分研究未说明利益冲突。结论31篇系统评价均得出中药制剂治疗2型糖尿病有效的结论,但其方法学质量有待提高且有效性需要更多高质量研究进一步证实。

Objectives To re-evaluate the Meta-analysis/systematic reviews of Chinese patent preparations for the treatment of type 2 diabetes mellitus.Methods Six databases including PubMed,Web of Science,Wiley,CNKI,WF and VIP were searched from inception to December 31,2021.The AMSTAR-2 scale,PRISMA statement were applied to evaluate the quality and normality of the 31 included documents.Results AMSTAR-2 methodological quality evaluation showed that 21 of the included Meta-analyses/systematic evaluations had a very low rating,3 had a low rating,and 7 had a moderate rating.The main downgrading factors were duration of follow-up and conflict of interest not stated.PRISMA scores ranged from 14-26,with a mean score of approximately 21.6,with most of the studies not describing conflicts of interest.Conclusion All 31 systematic evaluations concluded that Chinese patent preparations are effective in the treatment of type 2 diabetes,but their methodological quality needs to be improved and their effectiveness needs to be further confirmed by more high-quality studies.